WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability

Area of Science:

• Endocrinology
• Cell Biology
• Regenerative Medicine

Background:

• Diabetes mellitus treatment requires agents that stimulate human pancreatic beta cell proliferation.
• The small molecule WS6 has shown potential by stimulating beta cell proliferation, but its broader effects on human islets are not well understood.

Purpose of the Study:

• To conduct an in-depth phenotypic analysis of WS6-treated human islets.
• To explore WS6's effects on non-beta cell proliferation, beta cell differentiation, and islet cell viability.
• To evaluate WS6's potential as a beta cell regenerative therapy.

Main Methods:

• Culturing human islets and treating them with WS6.
• Performing phenotypic analysis to assess cell proliferation, differentiation, and viability.
• Quantifying beta and alpha cell proliferation and assessing beta cell markers.

Main Results:

• WS6 stimulated proliferation in both human beta cells and alpha cells, indicating it is not beta cell-specific.
• WS6 did not alter beta cell differentiation, as evidenced by stable insulin-positive cell proportions and transcription factor expression.
• WS6 had no adverse effects on human islet cell apoptosis or overall viability.

Conclusions:

• WS6 promotes proliferation of both human beta and alpha cells.
• WS6 maintains cellular viability and the differentiated phenotype of beta cells.
• These findings support WS6's potential to increase human islet mass for diabetes treatment.